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The chemokine superfamily consists of a large number of ligands and receptors. At first glance, this family
appears redundant and their ligand-receptor relationships promiscuous, making its study challenging.
However, analyzing this family from the evolutionary perspective greatly simplifies understanding both the
organization and function of this apparently complex system. In particular, the functions of a subgroup of
chemokines (designated homeostatic chemokines) have played pivotal roles in advancing our understanding
of the organization and function of the cellular networks that shape the immune system. Here, we update the
full scope of the human and mouse chemokine superfamilies and their relationships and summarize several
important roles that homeostatic chemokines play in the immune system.Introduction
Since the identification of the chemokines CXCL8 (IL-8) and
CCL2 (MCP-1) in the late 1980s, the chemokine superfamily
has expanded rapidly (Rollins, 1997; Yoshie et al., 2001; Zlotnik
and Yoshie, 2000; Zlotnik et al., 2006). An initial wave of
chemokine discovery occurred in the early 1990s, when some
chemokines that attracted neutrophils and monocytes were
discovered. Their identification was facilitated by the abundance
of their transcripts in activated cells that participate in inflamma-
tory responses. Their receptors were soon identified and were
found to be a subgroup of class A G protein-coupled receptors
(GPCRs) (Vassilatis et al., 2003). However, the initial ligand-
receptor relationships that were described were found to be
promiscuous: a single chemokine binds to several chemokine
receptors, whereas a single chemokine receptor has multiple
chemokine ligands. Moreover, the chemokine genes were
found to map to two discrete chromosomal sites, thus forming
two large gene clusters, one for CXC chemokines (in human,
4q13.3) and another for CC chemokines (in human, 17q12)
(Figure 1). Such unorthodox features of the chemokine system
along with their innate immunity roles attracted little attention
from immunologists during these early years. Most of these
chemokines are now classified as inflammatory, because they
play pivotal roles in controlling leukocyte recruitment during
inflammatory responses.
However, a ‘‘second round’’ of chemokine identification
started in the mid 1990s, facilitated by rapidly expanding EST
(expressed sequence tag) databases. In contrast to the inflam-
matory chemokines, the expression of these chemokines is
constitutive and restricted to specific cells or organs. Moreover,
in contrast to inflammatory chemokines that mainly attract
macrophages or neutrophils, they are chemotactic for subsets
of lymphocytes or dendritic cells, cells that mediate acquired
immunity. Indeed, many were found to play pivotal roles in
immune responses and in defining the cellular organization of
organs of the immune system. Their receptors also revealed far
less promiscuous interactions. In fact, many of them exhibit
highly restricted ligand-receptor relationships. In both the human
and mouse genomes, the genes encoding homeostatic chemo-
kines are located outside the familiar CXC and CC chemokineclusters (Figure 1). These findings have led to a paradigm
shift in our concept of chemokine function. The functional
characterization of these second-round chemokines led to
major advances in our understanding of the function and
organization of the immune system. It became apparent
that many homeostatic chemokines play major roles in the orga-
nization of the immune system and are indeed ‘‘master regula-
tors’’ of the movement and localization of lymphocyte and
dendritic cell subsets in the body (Moser et al., 2004; Zlotnik
et al., 2006). In this review, our objectives include updating
the classification and nomenclature of the chemokine super-
family, including the clarification of some nomenclature issues
concerning human and mouse chemokines. We also summarize
recent developments concerning functions of this interesting
gene family in the immune system and, finally, we comment on
its potential to yield therapeutics or biomarkers of human
disease.
Chemokine Nomenclature Updated
In our previous review (Zlotnik and Yoshie, 2000), we proposed
a systematic nomenclature of the chemokines that originated
at the Keystone symposium on Chemokines and Chemotactic
Receptors in 1999. This nomenclature system was quickly
accepted and has helped establish a standard chemokine
terminology that has greatly facilitated their study. However,
because of the rapid and divergent evolution of the chemokine
system, species like humans andmice exhibit differences in their
chemokine ligands (Zlotnik et al., 2006). The originally described
chemokine relationships between human and mouse were
based on sequence similarities and phylogenic analyses.
Consequently, there were some ambiguities in the assignment
of species counterparts. We now have more powerful tools,
including the human and mouse genomes, to improve on these
analyses. The genomic organization of the human and mouse
chemokine genes provides insights into the evolutionary forces
that shape this superfamily and also confirm that in some cases,
a given ligand exists in one species but not the other (Nomiyama
et al., 2010; Zlotnik et al., 2006). Given these advances, we need
to update the human and mouse chemokine nomenclature
systems.Immunity 36, May 25, 2012 ª2012 Elsevier Inc. 705
Figure 1. Chromosomal Map of the Human
Chemokine and Chemokine Receptor
Genes
The full set of human chromosomes is shown with
the locations of the chemokine (white) and
chemokine receptor (gray) genes indicated as
follows.
Immunity
ReviewSince 2000 (Zlotnik and Yoshie, 2000), in-depth analyses of
the mouse and human genomes have identified all the chemo-
kine genes. Table 1 contains the complete families of human
and mouse chemokines. The chemokine molecular signature
includes four conserved cysteine residues that form two
disulfide bonds pairing the first with the third and the second
with the fourth cysteines. Based on the arrangement of the
N-terminal two cysteine residues, chemokines are grouped706 Immunity 36, May 25, 2012 ª2012 Elsevier Inc.into four subfamilies: CXC, CC, (X)C,
and CX3C. In the CXC chemokines, one
amino acid separates the first two
cysteines, whereas in CC chemokines,
these two cysteines are adjacent. A single
member of the CX3C subfamily, CX3CL1
or fractalkine, has three amino acids
between the two cysteines, whereas the
first and third cysteines are missing in
the (X)C subfamily. Recently, another
possible type of chemokine (CX) has
been reported in zebrafish (Nomiyama
et al., 2008), which lack one of the two
N terminus cysteines but retain the third
and fourth ones; however, there is no
evidence that this latter kind of chemo-
kine exists in mammals.
Besides the structural criteria, chemo-
kines may be categorized into several
functional groups (Moser et al., 2004).
Inflammatory chemokines (termed ‘‘I’’ in
Table 1) are those upregulated under
inflammatory conditions and are mainly
involved in the recruitment of leukocytes
to inflamed tissues. Among them, CXC
chemokines with an ELR (Glu-Leu-Arg)
motif just prior to the first cysteine residue
are angiogenic, a property probably
mediated via the chemokine receptors
CXCR1 and CXCR2, whereas the ligands
CXCL4, CXCL9, CXCL10, and CXCL11
are non-ELR motif angiostatic chemo-
kines (Kiefer and Siekmann, 2011).
Homeostatic chemokines (termed ‘‘H’’ in
Table 1) are those expressed constitu-
tively in lymphoid or other organs and
normally mediate homeostatic migration
and homing of various cells (including
lymphocytes). Some chemokines overlap
both fields and are called dual-function
chemokines (termed ‘‘D’’ in Table 1).
These classifications are at best opera-tional and not mutually exclusive. Thus, some inflammatory
chemokines may have homeostatic functions, whereas some
homeostatic chemokines may be upregulated under certain
‘‘emergency’’ conditions.
Some chemokines, such as CCL14 and CCL15, are present at
high concentrations in serum, have an extended N terminus, and
are converted to high-affinity ligands by N-terminal cleavage.
CCL23 also has a long N terminus, is closely related to CCL15,
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chemokines termed plasma chemokines (‘‘P’’ for plasma or
precursor in Table 1) (Nomiyama et al., 2010). Yet another group
of chemokines represented by CXCL4, CXCL4L1, CXCL7, and
CCL5 are stored at high concentrations in a-granules of platelets
and quickly released upon platelet activation (Flad and Brandt,
2010). They probably have important roles as first-line inflamma-
tory mediators upon vascular injury. One of these, CXCL4 (PF4),
is one of the oldest members of the chemokine superfamily.
However, its biological significance is still obscure. Although
CXCR3-B (a CXCR3 slice variant) is believed to mediate the
angiostatic activity of CXCL4 and other non-ELR CXC chemo-
kines (CXCL9, CXCL10, CXCL11) (Lasagni et al., 2003), the
mechanism remains unknown. CXCL4L1 is the nonallelic variant
of CXCL4, differs from CXCL4 by only three amino acids within
the C terminus, and is more angiostatic than CXCL4 (Struyf
et al., 2004). CCL5 is one of the most versatile chemokines,
acting on as many as three chemokine receptors (CCR1,
CCR3, and CCR5), and is highly inducible in many cells. Further-
more, it is abundantly stored in a-granules of platelets and in
cytoplasmic granules of memory or effector CD8+ T cells as
well (Catalfamo et al., 2004). Functionally, CXCL4 and CCL5
appear to be closely associated, possibly through the formation
of heteroligomers. CXCL7 is stored in inactive form and upon
release is progressively processed at the N terminus by neutro-
phil cathepsin G from platelet basic protein (PBP) (aa 35–128) to
connective tissue activating peptide (CTAP-III) (aa 44–128), to
beta thromboglobulin (b-TG) (aa 48–128), and finally to neutro-
phil activating peptide (NAP-2) (aa 59–128), a high-affinity
CXCR2 ligand. Thus, neutrophil attraction and proteolytic activa-
tion of CXCL7 form an amplification loop. Meanwhile, PBP and
its processed products, along with CXCL4, have potent antimi-
crobial activities and are also called thrombocidins. Collectively,
these chemokines are often termed platelet chemokines (termed
‘‘Pt’’ for platelet in Table 1) (Flad and Brandt, 2010).
The differences between inflammatory and homeostatic
chemokines have an evolutionary origin, and it centers on the
rapid evolution of the former (Nomiyama et al., 2010). Inflamma-
tory chemokines are clustered in chromosome 4 and chromo-
some 17 in the human (Figure 1). The reason for such rapid
evolution in inflammatory chemokines is not clear but probably
is a result of strong selective pressure to increase their members
when early humans (or mice) faced a new pathogen that repre-
sented a serious threat to their survival. Furthermore, individual
inflammatory chemokines can also differ markedly in their func-
tion between species (Islam et al., 2011). Finally, many inflamma-
tory chemokines exist only in mouse or human (for example,
CXCL8, Cxcl15, etc.) (see Table 1); this is probably the result
of different pathogen-driven evolutionary experiences of the
mouse and human lineages. We should note that the original
nomenclature was aimed at the human chemokines, designated
in capital letters; themouse chemokines are designated in lower-
case letters (Table 1).
The rapid evolution of inflammatory chemokines often makes
the orthologous relationships obscure by phylogenic analysis,
even between human and mouse (Nomiyama et al., 2010). For
example, the three human paralogs CXCL1, CXCL2, and
CXCL3 are structurally similar, and the same applies to their
mouse counterparts (Nomiyama et al., 2010). It is thereforeimpossible to determine their orthologous relationships just
from phylogenic analyses. In such cases, analysis of the syntenic
regions between the two genomes can be used to correctly
assign species counterparts. The latter approach reveals that
the mouse orthologs of human CXCL6, CXCL4L1, CXCL1, and
CXCL3 correspond to Cxcl5, Cxcl4, Cxcl3, and Cxcl1, respec-
tively (Nomiyama et al., 2010). Indeed, mouse Cxcl5 is closer
to human CXCL6 than to CXCL5, and recently the rat gene
symbol Cxcl5 has been renamed Cxcl6 (Nomiyama et al.,
2010). Similar analyses in the CC chemokines indicate that the
mouse homologs of human CCL15 and CCL23 are Ccl9 and
Ccl6, respectively (Nomiyama et al., 2010).
Islam et al. (2011) have shown that, although mouse Ccl8 is
considered a member of the MCP (monocyte chemotactic
protein) subfamily, it does not signal via Ccr2 but is instead
a potent agonist for Ccr8, until now considered the sole receptor
for Ccl1. However, human CCL8 is not a CCR8 agonist. These
divergent results may be explained by the fact that mouse
Ccl8 is actually not the counterpart of human CCL8 but is
instead a mouse-specific chemokine like mouse Ccl12 (Table 1).
Conversely, human CCL13 has no mouse counterpart. The
chromosomal gene order of the human MCP-1 locus is CCL2-
CCL7-CCL11-CCL8-CCL13-CCL1 (note fourth and fifth genes),
whereas in the mouse it is Ccl2-Ccl7-Ccl11-Ccl12-Ccl8-Ccl1
(different fourth and fifth genes) (Nomiyama et al., 2010). Thus,
the correct relationships, if any, of these genetically related
chemokines still need to be determined. The importance of these
observations is obvious when studying the effects of these
chemokines in mouse models and their relevance to human
disease.
In contrast, homeostatic chemokines are located singly or in
miniclusters in different chromosomes (Figure 1). They are rela-
tively ancient in evolutionary terms, well conserved between
species, and function in a more predictable manner. For these
reasons, the conclusions of studies in genetically modified
mice deficient in homeostatic chemokines are more likely to
apply to human physiology.
Chemokine Receptors
Chemokine receptors are class A GPCRs coupled with the Gai
class of the heterotrimeric G proteins. They are also grouped
into four subfamilies according to the subfamily of their major
chemokine ligands (Zlotnik et al., 2006). Like the ligand counter-
part genes, the chemokine receptor genes also form clusters. A
large cluster is located in human chromosome 3 (Figure 1), sug-
gesting a rapid evolution through repeated gene duplications.
However, compared to the ligands, chemokine receptors are
relatively well conserved between species (including human
and mouse) (Nomiyama et al., 2011). Table 2 summarizes all
known chemokine receptors. So far, 18 chemokine receptors
with the standard Gai-dependent chemotactic activity have
been identified in human and mouse. Furthermore, five atypical
(nonchemotactic, recycling, or scavenging) chemokine recep-
tors have been described. It is apparent that the chemokine
receptors of inflammatory chemokines tend to have large
numbers of chemokine ligands, and some ligands are also
shared by multiple receptors (Nomiyama et al., 2011).
In another twist, some chemokines can also function as
natural chemokine antagonists of other ligand-receptor pairsImmunity 36, May 25, 2012 ª2012 Elsevier Inc. 707
Table 1. Human and Mouse Chemokines
Other Names
(Human)
Gene Symbol Other Names
(Mouse)
Receptor
Chemokine Category Human Mousea Agonistic Antagonistic
CXC Subfamily
CXCL1 GROa, MGSA I, ELR CXCL1 Cxcl3b Gm1960 CXCR2
CXCL2 GROb I, ELR CXCL2 Cxcl2 MIP-2 CXCR2
CXCL3 GROg I, ELR CXCL3 Cxcl1b KC CXCR2
CXCL4 PF4 Pt, non-ELR PF4 – CXCR3-B
CXCL4L1 PF4V1 Pt, non-ELR PF4V1 Pf4b CXCR3-B
CXCL5 ENA78 I, ELR CXCL5 – CXCR2
CXCL6 GCP2 I, ELR CXCL6 Cxcl5b LIX CXCR1, CXCR2
CXCL7 NAP-2 Pt, I, ELR PPBP Ppbp CXCR1, CXCR2
CXCL8 IL-8 I, ELR IL-8 – CXCR1, CXCR2
CXCL9 MIG I, non-ELR CXCL9 Cxcl9 CXCR3 CCR3
CXCL10 IP-10 I, non-ELR CXCL10 Cxcl10 CXCR3 CCR3
CXCL11 I-TAC I, non-ELR CXCL11 Cxcl11 CXCR3, CXCR7 CCR3, CCR5
CXCL12 SDF-1 H, non-ELR CXCL12 Cxcl12 CXCR4, CXCR7
CXCL13 BLC, BCA-1 H, non-ELR CXCL13 Cxcl13 CXCR5, CXCR3
CXCL14 BRAK H, non-ELR CXCL14 Cxcl14 unknown
– – U, non-ELR – Cxcl15 Lungkine,
Weche
unknown
CXCL16 SR-PSOX I CXCL16 Cxcl16 CXCR6
CXCL17 DMC U CXCL17 Cxcl17 unknown
CC Subfamily
CCL1 I-309 I CCL1 Ccl1 TCA-3 CCR8
CCL2 MCP-1 I CCL2 Ccl2 JE CCR2
CCL3 MIP-1a, LD78a I CCL3 Ccl3 CCR1, CCR5
CCL3L1 LD78b I CCL3L1 – CCR1, CCR3, CCR5
CCL3L3 LD78b I CCL3L3 –
CCL4 MIP-1b I CCL4 Ccl4 CCR5
CCL4L1 AT744.2 I CCL4L1 –
CCL4L2 – I CCL4L2 –
CCL5 RANTES I, Pt CCL5 Ccl5 CCR1, CCR3, CCR5
CCL7 MCP-3 I CCL7 Ccl7 MARC CCR1, CCR2, CCR3 CCR5
CCL8 MCP-2 I CCL8 – CCR1, CCR2, CCR5
– – I Ccl8b CCR8 (mouse)
CCL11 Eotaxin D CCL11 Ccl11 CCR3, CCR5 CXCR3, CCR2
– – I – Ccl12 MCP-5
CCL13 MCP-4 I CCL13 – CCR2, CCR3
CCL14 HCC-1 P CCL14 – CCR1, CCR3, CCR5
CCL15 HCC-2,
Leukotactin-1
P CCL15 Ccl9b CCF18, MIP-1g CCR1, CCR3
CCL16 LEC, HCC-4 U CCL16 – CCR1, CCR2, CCR5,
CCR8, H4
CCL17 TARC D CCL17 Ccl17 ABCD-2 CCR4
CCL18 PARC, DC-CK1 H CCL18 – PITPNM3 CCR3
CCL19 MIP-3b, ELC H CCL19 Ccl19 CCR7
CCL20 MIP-3a, LARC D CCL20 Ccl20 CCR6
CCL21 SLC, 6Ckine H CCL21 Ccl21a CCR7 CXCR3 (mouse)
– – H – Ccl21b CCR7
– – H – Ccl21c CCR7
CCL22 MDC D CCL22 Ccl22 ABCD-1 CCR4
708 Immunity 36, May 25, 2012 ª2012 Elsevier Inc.
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Table 1. Continued
Other Names
(Human)
Gene Symbol Other Names
(Mouse)
Receptor
Chemokine Category Human Mousea Agonistic Antagonistic
CCL23 MPIF-1 P CCL23 Ccl6b C10 CCR1, FPRL-1
CCL24 Eotaxin-2,
MPIF-2
H CCL24 Ccl24 CCR3
CCL25 TECK H CCL25 Ccl25 CCR9
CCL26 Eotaxin-3 I CCL26 (Ccl26) CCR3, CX3CR1 CCR1, CCR2,
CCR5
CCL27 CTACK, ILC H CCL27 Ccl27a CCR10
- - H - Ccl27b
CCL28 MEC H CCL28 Ccl28 CCR10, CCR3
XC Subfamily
XCL1 Lymphotactin,
ATAC, SCM-1a
D XCL1 Xcl1 lymphotactin XCR1
XCL2 SCM-1b D XCL2 – XCR1
CX3C Subfamily
CX3CL1 Fractalkine D CX3CL1 Cx3cl1 fractalkine,
neurotactin
CX3CR1
Abbreviations: I, inflammatory chemokines; H, homeostatic chemokines; D, dual chemokines; P, plasma or platelet chemokines that are activated by
cleavage; Pt, platelet chemokines; U, unknown.Mouse geneswhose human counterparts are reassigned by synteny analysis are highlighted by under-
line. H4, histamine receptor type 4; PITPNM3, phosphatidylinositole transfer protein membrane associated 3; FPRL-1, formyl peptide receptor like-1.
aGenes appearing in parentheses are not expressed.
bMouse gene whose human counterpart was reassigned after syntenic analysis.
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cally natural antagonists (Loetscher et al., 2001; Weng et al.,
1998). Thus, CXCL9, CXCL10, and CXCL11 are natural antago-
nists for CCR3, whereas CCL11 is a natural antagonist for
CXCR3. Given that CXCR3 is a T helper 1 (Th1) cell-associated
chemokine receptor, whereas CCR3 is expressed by Th2 cells
and eosinophils, this suggests that these chemokines can form
mutually exclusive microenvironments that favor either Th1 or
Th2 cell differentiation (Sallusto and Lanzavecchia, 2000).
Nonchemokine ligands can also bind certain chemokine
receptors. Though still controversial, N-acetyl Pro-Gly-Pro
(acPGP), a neutrophil protease-mediated degradation product
of extracellular matrix, can be a Cxcr1 and Cxcr2 agonist
(Weathington et al., 2006). Thus, production of this tripeptide
by infiltrating neutrophils may recruit yet more neutrophils via
Cxcr1 and Cxcr2. Macrophage migration inhibitory factor (MIF)
is an evolutionary conserved cytokine with proinflammatory
functions and has also been claimed to be a noncanonical
CXCR2 and CXCR4 ligand (Bernhagen et al., 2007). Extracellular
ubiquitin, which has anti-inflammatory properties, is another
nonchemokine CXCR4 ligand (Saini et al., 2010). Finally, the
nuclear protein HMGB1 can also interact with CXCL12 and
mediates mononuclear cell recruitment in vivo via CXCR4
(Schiraldi et al., 2012).
Antimicrobial peptides are natural antibiotics of multicellular
organisms and often exibit chemotactic activity. b-defensins
are antimicrobial peptides expressed by epithelial cells of the
body surface (Ouellette, 2011). Like CCL20, b-defensin-2
attracts immature dendritic and memory T cells via CCR6
(Yang et al., 1999). b-defensins 2 and 3 also function as nonca-
nonical ligands for CCR2 (Ro¨hrl et al., 2010). Conversely,a growing number of chemokines mediate direct antimicrobial
activities (Eliasson and Egesten, 2008). It is therefore possible
that chemokines and antimicrobial peptides share a common
evolutionary origin. Alternatively, the selective pressures exerted
by the pathogens on their hosts may have led the chemokines
and antimicrobial peptides to perform overlapping functions.
In contrast to inflammatory chemokine receptors, homeostatic
or dual-function chemokine receptors show more restricted
ligand usages: just one or two ligands (Table 2). Furthermore,
even in the case of two ligands, most are not just redundant
but appear instead to have specific roles. For example, CCR4,
which is expressed by Th2 cells, skin-homing T cells, and regu-
latory T cells, has two ligands: CCL17 and CCL22. In inflamed
skin tissues, CCL17 is expressed by skin microvascular endo-
thelial cells, whereas CCL22 is expressed by dermal dendritic
cells. Thus, CCR4-expressing T cells are first exposed to
CCL17 on skin endothelial cells and then guided into skin tissues
by CCL22 (Mariani et al., 2004). This sequential interaction of
ligands seems to be possible because CCL17 does not induce
desensitization of CCR4, whereas CCL22, being a stronger
ligand for CCR4, can override the prior effect of CCL17 to guide
T cells away from CCL17 (Mariani et al., 2004). Another example
is CCR7 and its two ligands, CCL19 and CCL21, which play an
essential role in the homing of lymphocytes and dendritic cells
to secondary lymphoid tissues. Although both CCL19 and
CCL21 are coexpressed in the T cell zone of secondary lymphoid
tissues, only CCL21 is expressed or presented by high endothe-
lial venules (HEV). Similarly, only CCL21 is expressed on afferent
lymphatic vessels. CCL21 but not CCL19 can also be immobi-
lized to the cell surface through its highly charged 40 amino
acid extension at the C terminus. On the other hand, onlyImmunity 36, May 25, 2012 ª2012 Elsevier Inc. 709
Table 2. Human and Mouse Chemokine Receptors
Human Gene
Symbol Other Names Category
Mouse Gene
Symbol
Ligands
Agonistic Antagonistic
CXCR Subfamily
CXCR1 IL-8RA I Cxcr1 CXCL6, CXCL7, CXCL8, acPGP
CXCR2 IL-8RB I Cxcr2 CXCL1, CXCL2, CXCL3, CXCL5, CXCL6,
CXCL7, CXCL8, acPGP, MIF
CXCR3 GPR9 I Cxcr3 CXCL4 (CXCR3-B), CXCL9, CXCL10,
CXCL11, CXCL13, CCL21 (mouse)
CCL11
CXCR4 LESTER, Fusin H Cxcr4 CXCL12, MIF, ubiquitin
CXCR5 BLR1 H Cxcr5 CXCL13
CXCR6 STRL33, BONZO H Cxcr6 CXCL16
CCR Subfamily
CCR1 CC-CKR-1 I Ccr1 CCL3, CCL3L1, CCL5, CCL7, CCL8,
CCL13, CCL14, CCL15, CCL16, CCL23
CCL26
CCR2 CC-CKR-2 I Ccr2 CCL2, CCL7, CCL8, CCL13, CCL16,
b-defensin 2,3
CCL11, CCL26
CCR3 CC-CKR-3 I Ccr3 CCL3L1, CCL5, CCL7, CCL11, CCL13,
CCL14, CCL15, CCL24, CCL26, CCL28
CXCL9, CXCL10,
CXCL11, CCL18
CCR4 CC-CKR-4 D Ccr4 CCL17, CCL22
CCR5 CC-CKR-5 I Ccr5 CCL3, CCL3L1, CCL4, CCL4L1, CCL5,
CCL8, CCL11, CCL16
CCL7, CXCL11,
CCL26
CCR6 STRL22, GPR29 I Ccr6 CCL20, b-defensin-2
CCR7 EBI1, BLR2 H Ccr7 CCL19, CCL21
CCR8 TER1, GPR-CY6 H Ccr8 CCL1, CCL8 (mouse)
CCR9 GPR-9-6 H Ccr9 CCL25
CCR10 GPR2 H Ccr10 CCL27, CCL28
XCR Subfamily
XCR1 GPR-5 D Xcr1 XCL1, XCL2
CX3CR Subfamily
CX3CR1 V28, GPR13 D Cx3cr1 CX3CL1, CCL26 (human)
Atypical (Nonchemotactic, Recycling or Scavenger Receptors)
CXCR7 RDC1, GPR159 Cxcr7 CXCL11, CXCL12
CCBP2 D6 Ccbp2 CCL2, CCL3, CCL3L1, CCL4, CCL4L1,
CCL5, CCL7, CCL8, CCL11, CCL12, CCL13,
CCL14, CCL17, CCL22, CCL23, CCL24
CCRL1 CCX-CKR Ccrl1 CCL19, CCL21, CCL25, CXCL13
CCRL2 HCR, CRAM Ccrl2 CCL19, chemerin
DARC Duffy Darc CXCL1, CXCL2, CXCL3, CXCL7, CXCL8,
CCL2, CCL5, CCL11, CCL13, CCL14, CCL17
Abbreviations: acPGP, N-acetyl Pro-Gly-Pro; MIF, macrophage migration inhibitory factor.
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(Nandagopal et al., 2011; Schumann et al., 2010). Thus, the likely
scenario is that CCL21 guides lymphocytes and dendritic cells
expressing CCR7 into lymph nodes and T cell zones via HEVs
and afferent lymphatics. Then, CCL19 overrides CCL21-
mediated migration and desensitizes CCR7. Downregulation of
CCR7 is also necessary for B and follicular helper T cells ex-
pressing CXCR5 to redirect their migration to the B cell zone
via CXCL13 expressed by follicular dendritic cells (Haynes
et al., 2007). These examples illustrate how a set of a single
receptor with a pair of chemokines can play a combinatorial or
functionally differential role in target cell migration.710 Immunity 36, May 25, 2012 ª2012 Elsevier Inc.Atypical Chemokine Receptors
There are also five atypical chemokine receptors (Table 2). They
can bind a large number of chemokine ligands. Recently, atyp-
ical or decoy chemokine receptors have attracted attention
because of their influence on the availability and function of
both inflammatory and homeostatic chemokines. They are not
just chemokine binding proteins, but standard heptahelical
membrane-spanning receptors similar to classical chemokine
receptors. Still, they do not transduce the full spectrum of
chemokine receptor signals that lead to chemotactic and other
cellular responses. This is partly because of either modification
or lack of the typical DRY motif in the second intracellular loop
Immunity
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Gai class G-proteins. Their functions include either chemokine
scavenger or decoy (interceptor) receptors or transporters.
There are excellent reviews on this subject (Mantovani et al.,
2006; Ulvmar et al., 2011). In brief, DARC (duffy antigen chemo-
kine receptor) is the classic example of an atypical chemokine
receptor. DARC binds a large number of CXC and CC inflamma-
tory but not homeostatic chemokines, is abundantly expressed
by erythrocytes, and functions as a chemokine sink. DARC is
also expressed by venular endothelial cells and mediates
chemokine transcytosis from the basolateral to the apical side.
This may promote leukocyte emigration at inflammation sites
(Pruenster and Rot, 2006). CCBP2(D6) is another atypical
chemokine receptor binding a large number of inflammatory
CC chemokines. Given that D6 is expressed by the endothelial
cells of afferent lymphatic vessels, its main role may be scav-
enging chemokines in the lymphatic flow to prevent leukocyte
activation within the lymphatics. Indeed,Ccpb2-/- mice exhibited
increased inflammatory responses in D6-expressing tissues
such as skin, placenta, lung, etc., when challenged with various
stimuli (Graham, 2009). CXCR7 is an interesting atypical chemo-
kine receptor (Maksym et al., 2009). Together with CXCR4 and
its ligand CXCL12, CXCR7 is conserved well across the verte-
brate species including sea lamprey (Nomiyama et al., 2011). It
binds CXCL11 and CXCL12. Importantly, CXCR7 can heterodi-
merize with CXCR4 and modulate the effect of CXCL12 on
CXCR4. Furthermore, CXCR7 can also signal in some cell types
although not by the classical G protein-coupled receptor path-
ways (Maksym et al., 2009). During embryogenesis, CXCR7 is
necessary for proper migration of primordial germ cells to
CXCL12 via CXCR4 by acting as a sink for CXCL12 (Boldajipour
et al., 2008). CXCR7 is also involved in cardiac tissue develop-
ment along with CXCR4 and CXCL12 (Sierro et al., 2007).
Although poorly expressed in normal adult tissues, CXCR7 is
widely expressed in a variety of tumors and tumor-associated
vessels and appears to promote tumor growth and neoangio-
genesis partly by signaling via mitogen activated protein kinase
(MAPK) cascades (Maksym et al., 2009). CCRL1 and CCRL2
differ from other atypical receptors in their ability to bind and
scavenge homeostatic chemokines, particularly the CCR7 axis
(Comerford et al., 2006; Leick et al., 2010). Thus, they are consid-
ered to play a regulatory role in the homeostatic migration of
lymphocytes and dendritic cells via CCR7. Interestingly, chem-
erin, a chemoattractant for myeloid-lineage cells including
myeloid and plasmacytoid dendritic cells and potential adipo-
kine signaling via ChemR23, also binds CCRL2 without signaling
(Bondue et al., 2011). CCRL2 has been shown to play an impor-
tant role in lung DC trafficking (Otero et al., 2010).
Chemokines and the Immune System
T Cell Plasticity
Chemokine receptors have been associated with specific polar-
ized subsets of CD4+ T cells that participate in various immune
responses. Th1 cells express CCR5 and CXCR3, whereas Th2
cells express CCR4 (Sallusto and Lanzavecchia, 2000) and
CCR8 (Zingoni et al., 1998). Th17 cells express CCR6 (Singh
et al., 2008) and this is likely to be the signal that recruits these
cells to the small intestine when it becomes colonized by the
microbiome (Esplugues et al., 2011), whereas T regulatory(Treg) cells express CCR4 (Hirahara et al., 2006) and also
CCR6 (Kitamura et al., 2010). These observations indicate that
different chemokine ligands, probably produced by antigen-pre-
senting or immunomodulatory cells, have the capacity to direct
the migration of these different subsets within the body (Sallusto
and Baggiolini, 2008). Chemokines can also influence macro-
phage plasticity and their interaction with lymphocytes (Biswas
and Mantovani, 2010).
Skin Chemokines
Several chemokines have evolved to be present in these tissues.
The most skin-associated chemokine is CCL27. Other chemo-
kines expressed in the skin include CXCL14 and several
inflammatory chemokines that are expressed in the skin under
inflammatory conditions. The roles of CCL17 and CCL22 as
well as their receptor CCR4 in the skin were discussed above.
CCL27 was originally called CTACK for cutaneous T cell
attracting chemokine (Morales et al., 1999). It is specifically
and strongly expressed in the skin by keratinocytes. CCL27
binds CCR10 (GPR2), a class A GPCR (Wang et al., 2000).
CCR10 is not widely expressed as other chemokine receptors;
instead, in the skin it is expressed strongly by melanocytes
(and also by melanoma cells). This skin expression pattern
suggests that the CCL27-CCR10 axis participates in skin
development, although a Ccr10-/- mouse does not exhibit skin
abnormalities (Morteau et al., 2008). A well-documented function
of the CCL27-CCR10 axis in the skin is the recruitment of
a subset of T cells to the skin that express cutaneous lymphocyte
antigen (CLA) (Morales et al., 1999). The function of these
skin-specific T cells remains obscure, but they are believed
to represent memory cells that participate in local responses
(Clark et al., 2006).
CXCL14 is a very interesting chemokine. It was originally
reported as BRAK (breast and kidney chemokine) because of
its high expression in these tissues (Hromas et al., 1999). It is,
along with CXCL12, one of the most conserved chemokines
(Zlotnik et al., 2006), suggesting that it has important evolu-
tionary functions. It exhibits microbicidal activity (Maerki et al.,
2009), suggesting that this may be its main role in the skin.
Mucosal Chemokines
Two chemokines are well known as mucosal chemokines
(CCL25 and CCL28) and two other chemokines (CXCL14 and
CXCL17) are also expressed in the mucosa but are not widely
known as mucosal chemokines. CCL25 was originally reported
as TECK (thymus-expressed chemokine) because it was origi-
nally isolated from the thymus where it exhibits very strong
expression (Vicari et al., 1997) and participates in T cell develop-
ment (see below). The only other site where it is strongly ex-
pressed is the small intestine (Vicari et al., 1997). Its receptor is
CCR9, another class A GPCR that does not exhibit a wide
expression pattern (Norment et al., 2000). Like the CCL27-
CCR10 axis, the CCL25-CCR9 axis is responsible for recruiting
a certain subset of T cells to the lamina propria of the intestine
(Kunkel et al., 2000) that express both CCR9 and a4b7 integrin
(Papadakis et al., 2000). These cells have become important
because they are involved in the pathogenesis of Crohn’s
disease and ulcerative colitis. In fact, several companies have
been developing CCL25-CCCR9 axis inhibitors and some of
these are in clinical trials in Crohn’s disease (Eksteen and
Adams, 2010).Immunity 36, May 25, 2012 ª2012 Elsevier Inc. 711
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expression of CCR9 in a subset of melanomas (Amersi et al.,
2008). The expression of certain homeostatic chemokine recep-
tors in tumor cells influences their metastatic potential (Zlotnik
et al., 2011). If tumor cells of a certain cancer express a given
homeostatic chemokine receptor, theymay preferentially metas-
tasize to organs where the ligand of that receptor is expressed.
Melanoma does not usually metastasize to the small intestine;
however, if melanoma tumor cells express CCR9, then intestinal
metastases are observed (Amersi et al., 2008).
CCL28 was originally identified as a product of epithelial cells
and also binds CCR10 (Wang et al., 2000). It is one of the most
mucosal-associated chemokines. It is highly expressed in the
salivary gland, the female reproductive tissues, and the
mammary gland (Bourges et al., 2008). It is detectable in saliva
and exhibits microbicidal activity (Hieshima et al., 2003). Inter-
estingly, its expression in the mammary gland is induced
upon the onset of lactation (Wilson and Butcher, 2004). CCL28
attracts plasmablasts that produce IgA through CCR10 (Kunkel
et al., 2003) and is responsible for the production of IgA in
certain mucosal sites (Hieshima et al., 2004; Morteau et al.,
2008). A Ccr10-/- mouse exhibits defective IgA responses in
the mammary gland (Morteau et al., 2008).
Less is known about the other two mucosal chemokines,
CXCL14 and CXCL17. CXCL14 is expressed in several mucosal
sites (Meuter and Moser, 2008; Shellenberger et al., 2004). In
some sites, CXCL14 can exhibit surprising expression speci-
ficity. For example, in the tongue, CXCL14 is strongly expressed
in the taste buds but not in lingual epithelium (Hevezi et al., 2009),
although its function there is currently unknown. CXCL14 is also
expressed in the intestines, and a Cxcl14-/- mouse shows meta-
bolic abnormalities (Nara et al., 2007) and also grows at a slower
rate (Tang et al., 2010). Because CXCL14 is a strongly conserved
chemokine, it is possible that these defects reflect develop-
mental abnormalities. Importantly, its receptor has not been
identified yet.
CXCL17was the last chemokine to be reported and character-
ized (Pisabarro et al., 2006) and there is little information about it
in the literature. Originally reported as DMC (dendritic cell and
macrophage chemokine), it is the last human chemokine ligand
of the CXC family. It is expressed in stomach and trachea
(Pisabarro et al., 2006). It has recently been confirmed to be
a mucosal chemokine because its expression is restricted to
bronchus and trachea, tongue, oral cavity, stomach, small intes-
tine, and colon and it exhibits microbicidal activity (A.M. Bur-
khardt, K.I. Tai, J.P. Flores-Gutierrez, M. Vilches-Cisneros, K.
Kamdar, O. Barbosa-Quintana, R. Valle-Rios, P.A. Hevezi, A.J.
Ouellette, and A.Z., in press). In contrast to CXCL14 that in the
tongue is expressed in the taste buds, CXCL17 is expressed in
the lingual epithelium but not in the taste buds (A.M. Burkhardt,
K.I. Tai, J.P. Flores-Gutierrez, M. Vilches-Cisneros, K. Kamdar,
O. Barbosa-Quintana, R. Valle-Rios, P.A. Hevezi, A.J. Ouellette,
and A.Z., unpublished data). This is an example of highly specific
expression patterns that chemokines can have in the mucosa,
although its functional significance is currently unknown. It
attracts dendritic cells and monocytes (Pisabarro et al., 2006)
and is induced by VEGF (vascular endothelial growth factor)
(Weinstein et al., 2006). Like CXCL14, its receptor is currently
unknown.712 Immunity 36, May 25, 2012 ª2012 Elsevier Inc.Chemokines in T Cell Development
Several chemokines are highly expressed in sites of lymphoid
development like the thymus, bone marrow, or fetal liver. There
are specific examples of chemokines important in lymphoid
development. One of these is theCCL25-CCR9 axis, which plays
an important role in T cell development in the thymus (Vicari
et al., 1997).
T cell development in the thymus commences when hemato-
poietic precursors from the bone marrow colonize the thymus.
Some chemokines participate in the seeding of the thymus rudi-
ment by hematopoietic bone marrow precursors. Ccr7-/- and
Ccr9-/- mice were shown to exhibit defective thymus coloniza-
tion (Krueger et al., 2010; Zlotoff et al., 2010). A more recent
study used a triple-deficient mouse (CXCR4, CCR7, and
CCR9) and observed a more profound defect (Caldero´n and
Boehm, 2011), suggesting that several chemokines participate
in this seeding process.
Once early T cell progenitors enter the thymus, they are
CD4CD8 (double-negative, DN) and are not yet committed
to the T cell lineage (Godfrey and Zlotnik, 1993). These are called
DN1. As they commit to the T cell lineage, they become DN2 and
start to rearrange the b chain of the T cell receptor (TCR)
(Godfrey et al., 1994) and subsequently become DN3. DN3
thymocytes that successfully rearrange the TCRb chain in-frame
express this chain with the pre-T alpha (Kometani et al., 2008)
and undergo ‘‘beta selection,’’ a step that allows the developing
DN3 thymocytes to proceed become DN4. As a result of beta
selection, DN3 thymocytes start to express CCR9 (Norment
et al., 2000) and this allows them to become CD4+CD8+ thymo-
cytes. CCR9 is also required for progression from the CD4+CD8+
stage to mature CD4+ thymocytes (Svensson et al., 2008). Other
chemokine receptors like CCR7 are also involved in T cell devel-
opment in the thymus (Misslitz et al., 2006).
Chemokines and Stem Cells
Hematopoietic stem cells (HSCs) are known to reside in the bone
marrow. Broxmeyer et al. (2005) reported that the CXCR4
inhibitor AMD3100 induced release of HSCs from the bone
marrow, indicating that the CXCR4-CXCL12 axis is a key signal
maintaining HSCs in the bone marrow. This observation had
potential clinical utility, because certain cancer patients are
candidates for whole-body irradiation followed by reconstitution
of the hematopoietic compartment via HSCs. Thus, the ability of
the CXCR4 antagonist AMD3100 to release HSCs from the
bone marrow meant that these ‘‘mobilized’’ HSCs could be
isolated from the blood of the patient in sufficient numbers to
permit repopulation with autologous HSCs (Uy et al., 2008).
Interestingly, AMD3100 synergizes with granulocyte colony
stimulating factor to mobilize HSCs, improving the effectiveness
of the approach and allowing the isolation of enough cells for
autologous cell transplantation. This combined approach has
been used in patients with non-Hodgkin’s lymphoma and with
multiple myeloma (Pusic and DiPersio, 2010). Other CXCR4-
based therapeutics have been reviewed recently (Peled et al.,
2012).
These developments underscore the important roles that
CXCR4 plays in development. Other studies have documented
that the CXCL12-CXCR4 axis plays pivotal roles in homing of
various stem cells to particular places of the embryo during
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understand these mechanisms has been the zebrafish, where
CXCR4 is the signal that guides stem cells that give rise to the
gonads of the developing fish embryo (Doitsidou et al., 2002;
Knaut et al., 2003). More recent studies have documented the
coordinated roles of CXCR4, CXCL12, and CXCR7 in the devel-
opment of the central nervous system in the zebrafish (Diotel
et al., 2010; Tiveron and Cremer, 2008). Thus, certain homeo-
static chemokine receptors play key roles in the homing of
various stem cells. The ability of the CXCR4-CXCL12 axis in
directing stem cell homing is probably related to its prominent
role in directing the metastatic destination of tumor cells as
well (Zlotnik et al., 2011).
Clinical Application of Chemokines
Chemokine Receptor Antagonists as Therapeutics
As discussed above, inflammatory chemokines are involved in
control of inflammatory responses and several homeostatic
chemokines are important in the control of immune responses,
and their roles in development and cell migration also make
them compelling targets for drug development. However, only
recently have two drugs that target chemokine receptors been
approved. One of these is a CCR5 antagonist that is approved
for inhibition of entry of human immunodeficiency virus (HIV)
into CCR5-positive cells (Gilliam et al., 2011). The other is
a CXCR4 antagonist (AMD3100) that has been approved for
mobilization of human hematopoietic stem cells from the bone
marrow (Keating, 2011). The latter therapeutic use of a CXCR4
antagonist was predicted after the observation that blocking
CXCR4 resulted in release of hematopoietic stem cells from
the bone marrow (Broxmeyer et al., 2005). This approach is
now used to obtain enough hematopoietic stem cells for use in
autologous bone marrow transplants in patients with non-
Hodgkin’s lymphoma or multiple myeloma (Pusic and DiPersio,
2010).
Despite the predominant role that chemokines play in
inflammatory responses, no chemokine-based drugs have
been approved for autoimmune or inflammatory diseases. One
possibility, as discussed above, is that animal models used for
preclinical studies aimed to evaluate the role of inflammatory
chemokines may not translate well for human diseases. Another
possibility is that more focused targets will succeed in specific
indications. For example, CCR9 antagonists are currently in
clinical trials for inflammatory bowel diseases (Proudfoot et al.,
2010), and CXCR3 antagonists (presumably because they target
Th1 cell responses) also show promise in other indications (Liu
et al., 2011). CCR4 may also be a target for adult T cell
leukemia-lymphomas (Tobinai et al., 2012).
Can Chemokines Be Biomarkers?
Molecular characterization of various human diseases by gene
arrays indicates that despite the complexity of this superfamily,
chemokines usually exhibit remarkable specificity in their associ-
ation with certain human diseases. This suggests another
possible use of chemokines, namely, as potential biomarkers.
One example is hepatitis C, which is caused by the hepatitis C
virus that infects the human liver. Until recently the treatment for
chronic carriers was a combination therapy of interferon alpha
(IFN-a) and ribavirin, but 50% of the patients failed to clear the
virus after this treatment (Tanaka et al., 2009). Infection withthe hepatitis C virus modulates the expression of many genes
in the infected liver, including two chemokines, CXCL9 and
CXCL10, which are strongly induced in the HCV-infected human
liver (Hevezi et al., 2011). IL-28B is a cytokine that has been asso-
ciated with the response to pegylated IFN-a and ribavirin in
chronic hepatitis C patients (Ge et al., 2009; Tanaka et al.,
2009). Darling et al. (2011) found that lower CXCL10 serum
concentrations correlate with sustained virological response,
whereas high pretreatment CXCL10 amounts in serum correlate
with nonresponders. Thus, the combination of IL-28B single-
nucleotide polymorphism (SNP) analyses along with CXCL10
serum concentrations may be effective predictors of response
to treatment in hepatitis C patients (Albert et al., 2011).
Alterations in plasma CXCL10 concentrations have also been
associated with onset of transplant rejection (Romagnani and
Crescioli, 2012). Given that CXCL10 is a ligand of CXCR3
and the latter is associated with Th1 cell responses (Sallusto
and Lanzavecchia, 2000), it is possible that serum CXCL10
concentrations may reflect Th1 cell response activity in vivo.
High CXCL10 concentrations may also correlate with poor prog-
nosis and metastasis in colorectal cancer (Toiyama et al., 2012).
More information on this subject has been presented elsewhere
(Amanatidou et al., 2011; Balkwill, 2012; Melve et al., 2011).Concluding Remarks
In order to understand the chemokine superfamily and its func-
tions in the organism, it is better to study it from an evolutionary
perspective. Whereas the function of inflammatory chemokines
is more probably linked to resistance to infectious agents,
homeostatic chemokines exhibit specific functions related to
their expression site(s). Chemokines participate in the develop-
ment of the immune system, in inflammatory responses, and in
innate and acquired immune responses. The discoveries and
accumulated knowledge in chemokine biology in the last
25 years have led to important advances in our understanding
of immune responses and organization of the immune system.
It is our hope that this review will help readers better understand
the chemokine superfamily.ACKNOWLEDGMENTS
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